# APBA Kısa Özet

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lisraya (brepocitinib), a once-daily oral tablet classified as a Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitor. This marks the first FDA-approved therapeutic option specifically indicated for adult patients with dermatomyositis, a rare autoimmune connective tissue disease characterized by muscle weakness and skin involvement.

# Çalışma neyi araştırdı?

The FDA’s decision was primarily informed by the results of a phase 3 randomized, double-blind, placebo-controlled trial (NCT05437263) involving 241 adult participants with dermatomyositis. The study evaluated the efficacy and safety of Lisraya 30 mg administered once daily over a 52-week treatment period. Key secondary objectives included assessing improvements in physical function, skin disease activity, and the ability to reduce concomitant corticosteroid use.

# Yöntem

The pivotal trial employed a randomized, double-blind, placebo-controlled design. Eligible adults with a confirmed diagnosis of dermatomyositis were randomized to receive either Lisraya 30 mg once daily or matching placebo. The trial was multicenter and maintained blinding throughout the 52-week treatment phase. Efficacy assessments were based on validated clinical endpoints, including the Total Improvement Score (TIS), which integrates multiple domains of disease impact. Corticosteroid tapering was also a structured component of the protocol.

# Temel bulgular

At the primary and key secondary timepoints, patients treated with Lisraya 30 mg demonstrated statistically and clinically meaningful improvements compared to the placebo group:

Total Improvement Score (TIS): Participants receiving Lisraya 30 mg achieved a higher average TIS at week 52, indicating greater overall clinical response and disease control. Physical Function: Improvements in validated measures of physical function were observed, reflecting enhanced mobility and daily living activities. Skin Disease Activity: Significant reductions in skin disease severity were reported, addressing a core symptomatic burden of dermatomyositis. Corticosteroid Reduction: A higher proportion of patients on Lisraya were able to reduce their corticosteroid dosage compared to those on placebo, which is a critical outcome given the long-term risks associated with steroid use.

# Bulgular ne anlama geliyor?

The approval of Lisraya represents the first specific pharmacological intervention for adult dermatomyositis in the oral formulation category. For patients and clinicians, this option provides a mechanism to address both muscle and skin manifestations of the disease through a targeted oral pathway. The ability to reduce corticosteroid exposure is particularly significant, as minimizing steroid use is a primary goal in the chronic management of inflammatory myopathies to mitigate associated metabolic and skeletal risks.

# Klinik önem

From a clinical perspective, the availability of an oral JAK/TYK2 inhibitor expands the treatment paradigm for dermatomyositis. Traditional management has relied heavily on corticosteroids and immunosuppressants with varying side-effect profiles. Lisraya offers a targeted oral alternative; however, prescribers should note that this approval was granted under the FDA’s accelerated approval pathway. This means that while clinical benefit has been demonstrated, the manufacturer is required to conduct further post-marketing studies to verify and describe the long-term clinical benefit and safety profile.

# Sınırlılıklar

Several limitations of the supporting data and the current approval status should be observed:

Study Population: The phase 3 trial enrolled adults with dermatomyositis; data regarding pediatric populations, other dermatomyositis subtypes, or concomitant disease states are not available from this specific study. Duration: The primary data cutoff was at 52 weeks. The durability of treatment effect and safety beyond one year are not established by the current press announcement. Precision: As with many trials in rare diseases, the sample size of 241 participants, while adequate for the primary endpoints, limits the precision of rare adverse event detection and long-term effect estimates. Long-Term Safety: The press release does not describe open-label extension data or long-term follow-up beyond the initial 52-week period. Ongoing post-marketing surveillance will be essential for characterizing the safety trajectory of chronic JAK/TYK2 inhibition in this patient group.

Disclaimer: This content is for research and informational purposes only and does not constitute clinical advice. Decisions regarding therapeutic use should be made in consultation with a qualified healthcare professional based on the full prescribing information and individual patient assessment.